Literature DB >> 25853497

Genital herpes: oral antiviral treatments.

Lisa M Hollier1, Catherine Eppes.   

Abstract

INTRODUCTION: Genital herpes is an infection with herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), and is among the most common sexually transmitted diseases. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of different oral antiviral treatments versus each other for a first episode of genital herpes in HIV-negative people? What are the effects of different antiviral treatments for genital herpes in HIV-positive people? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found eight studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: aciclovir, famciclovir, and valaciclovir.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25853497      PMCID: PMC4389798     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  28 in total

1.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

2.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

3.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland.

Authors:  J S Smith; M Rosinska; A Trzcinska; J M Pimenta; B Litwinska; J Siennicka
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

5.  Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey.

Authors:  A L Cunningham; R Taylor; J Taylor; C Marks; J Shaw; A Mindel
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

6.  Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.

Authors:  Edwin DeJesus; Anna Wald; Terri Warren; Timothy W Schacker; Sylvie Trottier; Mohsen Shahmanesh; Joanne L Hill; Clare A Brennan
Journal:  J Infect Dis       Date:  2003-09-10       Impact factor: 5.226

7.  Recurrence rates in genital herpes after symptomatic first-episode infection.

Authors:  J Benedetti; L Corey; R Ashley
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

Review 8.  Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.

Authors:  Fujun Li; Hans Maag; Tom Alfredson
Journal:  J Pharm Sci       Date:  2008-03       Impact factor: 3.534

Review 9.  Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

Authors:  Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

10.  An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.

Authors:  Katharine J Looker; Geoffrey P Garnett; George P Schmid
Journal:  Bull World Health Organ       Date:  2008-10       Impact factor: 9.408

View more
  1 in total

1.  Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Sita Awasthi; Peiwen Lu; Derek A Pullum; David A Dixon; Akiko Iwasaki; Harvey M Friedman
Journal:  NPJ Vaccines       Date:  2019-08-01       Impact factor: 7.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.